These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

328 related items for PubMed ID: 27181090

  • 21. Neurological Complications Associated With Anti-Programmed Death 1 (PD-1) Antibodies.
    Kao JC, Liao B, Markovic SN, Klein CJ, Naddaf E, Staff NP, Liewluck T, Hammack JE, Sandroni P, Finnes H, Mauermann ML.
    JAMA Neurol; 2017 Oct 01; 74(10):1216-1222. PubMed ID: 28873125
    [Abstract] [Full Text] [Related]

  • 22. Programmed Cell Death-1 Inhibitor-Induced Type 1 Diabetes Mellitus.
    Clotman K, Janssens K, Specenier P, Weets I, De Block CEM.
    J Clin Endocrinol Metab; 2018 Sep 01; 103(9):3144-3154. PubMed ID: 29955867
    [Abstract] [Full Text] [Related]

  • 23. Checkpoint Inhibitor-Associated Autoimmune Diabetes Is Distinct From Type 1 Diabetes.
    Tsang VHM, McGrath RT, Clifton-Bligh RJ, Scolyer RA, Jakrot V, Guminski AD, Long GV, Menzies AM.
    J Clin Endocrinol Metab; 2019 Nov 01; 104(11):5499-5506. PubMed ID: 31265074
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Nivolumab-induced acute-onset type 1 diabetes mellitus as an immune-related adverse event: A case report.
    Hatakeyama Y, Ohnishi H, Suda K, Okamura K, Shimada T, Yoshimura S.
    J Oncol Pharm Pract; 2019 Dec 01; 25(8):2023-2026. PubMed ID: 30526346
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Simultaneous development of Graves' disease and type 1 diabetes during anti-programmed cell death-1 therapy: A case report.
    Kurihara S, Oikawa Y, Nakajima R, Satomura A, Tanaka R, Kagamu H, Shimada A.
    J Diabetes Investig; 2020 Jul 01; 11(4):1006-1009. PubMed ID: 31926048
    [Abstract] [Full Text] [Related]

  • 28. Nivolumab and pembrolizumab as immune-modulating monoclonal antibodies targeting the PD-1 receptor to treat melanoma.
    Faghfuri E, Faramarzi MA, Nikfar S, Abdollahi M.
    Expert Rev Anticancer Ther; 2015 Jul 01; 15(9):981-93. PubMed ID: 26313415
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. A case of fulminant type 1 diabetes mellitus, with a precipitous decrease in pancreatic volume, induced by nivolumab for malignant melanoma: analysis of HLA and CTLA-4 polymorphisms.
    Ishikawa K, Shono-Saito T, Yamate T, Kai Y, Sakai T, Shimizu F, Yamada Y, Mori H, Noso S, Ikegami H, Kojima H, Tanaka H, Fujiwara S, Hatano Y.
    Eur J Dermatol; 2017 Apr 01; 27(2):184-185. PubMed ID: 27934619
    [No Abstract] [Full Text] [Related]

  • 31. Diabetic Ketoacidosis as a Delayed Immune-Related Event after Discontinuation of Nivolumab.
    Mae S, Kuriyama A, Tachibana H.
    J Emerg Med; 2021 Mar 01; 60(3):342-344. PubMed ID: 33097350
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy.
    Hofmann L, Forschner A, Loquai C, Goldinger SM, Zimmer L, Ugurel S, Schmidgen MI, Gutzmer R, Utikal JS, Göppner D, Hassel JC, Meier F, Tietze JK, Thomas I, Weishaupt C, Leverkus M, Wahl R, Dietrich U, Garbe C, Kirchberger MC, Eigentler T, Berking C, Gesierich A, Krackhardt AM, Schadendorf D, Schuler G, Dummer R, Heinzerling LM.
    Eur J Cancer; 2016 Jun 01; 60():190-209. PubMed ID: 27085692
    [Abstract] [Full Text] [Related]

  • 34. Rapid onset type-1 diabetes and diabetic ketoacidosis secondary to nivolumab immunotherapy: a review of existing literature.
    Abdullah HMA, Elnair R, Khan UI, Omar M, Morey-Vargas OL.
    BMJ Case Rep; 2019 Aug 26; 12(8):. PubMed ID: 31451458
    [Abstract] [Full Text] [Related]

  • 35. Characterization and Prognostic Significance of Cutaneous Adverse Events to Anti-Programmed Cell Death-1 Therapy.
    Lee YJ, Kim HT, Won CH, Chang SE, Lee MW, Choi JH, Lee WJ.
    J Korean Med Sci; 2019 Jul 08; 34(26):e186. PubMed ID: 31269545
    [Abstract] [Full Text] [Related]

  • 36. Type 1 diabetes mellitus induced by PD-1 inhibitors in China: a report of two cases.
    Luo J, Feng J, Liu C, Yang Z, Zhan D, Wu Y, Pan L, Zhang L.
    J Int Med Res; 2022 Sep 08; 50(9):3000605221121940. PubMed ID: 36171723
    [Abstract] [Full Text] [Related]

  • 37. Clinical Features of Nivolumab-Induced Thyroiditis: A Case Series Study.
    Yamauchi I, Sakane Y, Fukuda Y, Fujii T, Taura D, Hirata M, Hirota K, Ueda Y, Kanai Y, Yamashita Y, Kondo E, Sone M, Yasoda A, Inagaki N.
    Thyroid; 2017 Jul 08; 27(7):894-901. PubMed ID: 28537531
    [Abstract] [Full Text] [Related]

  • 38. Acute-onset diabetes mellitus with ketoacidosis in a nivolumab-treated patient with hepatocellular carcinoma.
    Harsch IA, Konturek PC.
    Wiad Lek; 2018 Jul 08; 71(5):945-948. PubMed ID: 30176620
    [Abstract] [Full Text] [Related]

  • 39. Precipitation of autoimmune diabetes with anti-PD-1 immunotherapy.
    Hughes J, Vudattu N, Sznol M, Gettinger S, Kluger H, Lupsa B, Herold KC.
    Diabetes Care; 2015 Apr 08; 38(4):e55-7. PubMed ID: 25805871
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 17.